Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Am J Kidney Dis. 2012 Nov;60(5):804-11. doi: 10.1053/j.ajkd.2012.06.017. Epub 2012 Jul 25.
Abnormal levels of both albuminuria and estimated glomerular filtration rate (eGFR) have been reported separately to be associated with cardiovascular risk. This study assessed the contribution of each separately in correctly identifying individuals at cardiovascular risk in the general population beyond traditional risk markers.
Prospective community-based cohort study.
SETTING & PARTICIPANTS: 8,507 individuals from the city of Groningen in the Netherlands followed up for 10.5 years for cardiovascular morbidity and mortality.
The contribution of albuminuria and eGFR separately on top of the traditional Framingham risk factors was assessed.
The composite of first occurrence of myocardial infarction, stroke, ischemic heart disease, revascularization procedure, and all-cause mortality.
At the baseline visit, albuminuria was measured in 2 consecutive 24-hour urine samples. eGFR was calculated using the serum creatinine-based CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.
In multivariable Cox regression models, albuminuria, but not eGFR, was associated independently with the primary study outcome (HR, 1.08 [95% CI, 1.04-1.12] per doubling of albuminuria). When added to the risk model consisting of Framingham risk factors, albuminuria significantly contributed to better risk stratification, shown by an increase in net reclassification index of 7.2% (95% CI, 3.3%-11.0%; P<0.001) and increase in relative incremental discrimination improvement of 3.0% (95% CI, 0.9%-5.1%; P=0.006).
The cohort includes mainly individuals of European ancestry. Therefore, results should not be extrapolated to other ethnicities.
In a general population cohort, albuminuria, but not eGFR, significantly adds to traditional cardiovascular risk factors in identifying individuals at risk of cardiovascular morbidity and all-cause mortality.
已有研究分别报道白蛋白尿和估算肾小球滤过率(eGFR)水平异常与心血管风险相关。本研究评估了在传统风险标志物之外,每种标志物单独用于正确识别普通人群中处于心血管风险的个体的能力。
前瞻性社区为基础的队列研究。
荷兰格罗宁根市的 8507 名个体,随访 10.5 年,观察心血管发病率和死亡率。
评估白蛋白尿和 eGFR 分别在传统弗雷明汉危险因素基础上的贡献。
首次发生心肌梗死、卒中和缺血性心脏病、血运重建和全因死亡率的复合结局。
在基线检查时,通过连续两次 24 小时尿液样本测量白蛋白尿。使用基于血清肌酐的 CKD-EPI(慢性肾脏病流行病学合作)方程计算 eGFR。
在多变量 Cox 回归模型中,白蛋白尿而非 eGFR 与主要研究结局独立相关(每增加一倍白蛋白尿的 HR 为 1.08[95%CI,1.04-1.12])。当添加到由弗雷明汉危险因素组成的风险模型中时,白蛋白尿显著提高了风险分层能力,净重新分类指数增加了 7.2%(95%CI,3.3%-11.0%;P<0.001),相对增量判别改善增加了 3.0%(95%CI,0.9%-5.1%;P=0.006)。
该队列主要包括欧洲血统的个体。因此,结果不应推断至其他种族。
在普通人群队列中,白蛋白尿而非 eGFR 显著增加了传统心血管危险因素,有助于识别处于心血管发病和全因死亡风险的个体。